PRPH Quote, Financials, Valuation and Earnings

Fonar has a net margin of -209.38% compared to ProPhase Labs's net margin of 9.23%. ProPhase Labs's return on equity of -144.22% beat Fonar's return on equity of 5.33%.

ProPhase Labs has a consensus price target of $13.80, signalling upside risk potential of 3842.86%. On the other hand Fonar has an analysts' consensus of -- which suggests that it could fall by --. Given that ProPhase Labs has higher upside potential than Fonar, analysts believe ProPhase Labs is more attractive than Fonar.

ProPhase Labs has a beta of -0.472, which suggesting that the stock is 147.175% less volatile than S&P 500. In comparison Fonar has a beta of 1.003, suggesting its more volatile than the S&P 500 by 0.30600000000001%.

ProPhase Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fonar offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs pays -- of its earnings as a dividend. Fonar pays out -- of its earnings as a dividend.

ProPhase Labs quarterly revenues are $1.4M, which are smaller than Fonar quarterly revenues of $27.2M. ProPhase Labs's net income of $4M is higher than Fonar's net income of $2.5M. Notably, ProPhase Labs's price-to-earnings ratio is -- while Fonar's PE ratio is 11.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs is 1.90x versus 0.89x for Fonar. Usually stocks with elevated PS ratios are considered overvalued.

OncoCyte has a net margin of -209.38% compared to ProPhase Labs's net margin of -312.02%. ProPhase Labs's return on equity of -144.22% beat OncoCyte's return on equity of -693.81%.

ProPhase Labs has a consensus price target of $13.80, signalling upside risk potential of 3842.86%. On the other hand OncoCyte has an analysts' consensus of $5.42 which suggests that it could grow by 62.66%. Given that ProPhase Labs has higher upside potential than OncoCyte, analysts believe ProPhase Labs is more attractive than OncoCyte.

ProPhase Labs has a beta of -0.472, which suggesting that the stock is 147.175% less volatile than S&P 500. In comparison OncoCyte has a beta of 0.953, suggesting its less volatile than the S&P 500 by 4.749%.

ProPhase Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OncoCyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs pays -- of its earnings as a dividend. OncoCyte pays out -- of its earnings as a dividend.

ProPhase Labs quarterly revenues are $1.4M, which are smaller than OncoCyte quarterly revenues of $2.1M. ProPhase Labs's net income of $4M is higher than OncoCyte's net income of -$6.7M. Notably, ProPhase Labs's price-to-earnings ratio is -- while OncoCyte's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs is 1.90x versus 15.10x for OncoCyte. Usually stocks with elevated PS ratios are considered overvalued.

Veracyte has a net margin of -209.38% compared to ProPhase Labs's net margin of 6.16%. ProPhase Labs's return on equity of -144.22% beat Veracyte's return on equity of 2.85%.

ProPhase Labs has a consensus price target of $13.80, signalling upside risk potential of 3842.86%. On the other hand Veracyte has an analysts' consensus of $40.50 which suggests that it could grow by 51.57%. Given that ProPhase Labs has higher upside potential than Veracyte, analysts believe ProPhase Labs is more attractive than Veracyte.

ProPhase Labs has a beta of -0.472, which suggesting that the stock is 147.175% less volatile than S&P 500. In comparison Veracyte has a beta of 2.145, suggesting its more volatile than the S&P 500 by 114.466%.

ProPhase Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs pays -- of its earnings as a dividend. Veracyte pays out -- of its earnings as a dividend.

ProPhase Labs quarterly revenues are $1.4M, which are smaller than Veracyte quarterly revenues of $114.5M. ProPhase Labs's net income of $4M is lower than Veracyte's net income of $7M. Notably, ProPhase Labs's price-to-earnings ratio is -- while Veracyte's PE ratio is 65.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs is 1.90x versus 4.56x for Veracyte. Usually stocks with elevated PS ratios are considered overvalued.

XWELL has a net margin of -209.38% compared to ProPhase Labs's net margin of -67.19%. ProPhase Labs's return on equity of -144.22% beat XWELL's return on equity of -153.74%.

ProPhase Labs has a consensus price target of $13.80, signalling upside risk potential of 3842.86%. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 703.67%. Given that ProPhase Labs has higher upside potential than XWELL, analysts believe ProPhase Labs is more attractive than XWELL.

ProPhase Labs has a beta of -0.472, which suggesting that the stock is 147.175% less volatile than S&P 500. In comparison XWELL has a beta of 1.014, suggesting its more volatile than the S&P 500 by 1.396%.

ProPhase Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs pays -- of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend.

ProPhase Labs quarterly revenues are $1.4M, which are smaller than XWELL quarterly revenues of $7M. ProPhase Labs's net income of $4M is higher than XWELL's net income of -$4.7M. Notably, ProPhase Labs's price-to-earnings ratio is -- while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs is 1.90x versus 0.13x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.